COGT Fundamental Analysis - COGENT BIOSCIENCES INC

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to COGT. COGT was compared to 538 industry peers in the Biotechnology industry. While COGT seems to be doing ok healthwise, there are quite some concerns on its profitability. COGT is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

COGT had negative earnings in the past year.

COGT had a negative operating cash flow in the past year.

COGT had negative earnings in each of the past 5 years.

COGT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

COGT has a worse Return On Assets (-74.40%) than 65.43% of its industry peers.

Looking at the Return On Equity, with a value of -131.89%, COGT is doing worse than 60.78% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-74.4%
ROE	-131.89%
ROIC	N/A

ROA(3y)-52.46%

ROA(5y)-51.99%

ROE(3y)-64.47%

ROE(5y)-60.7%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for COGT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, COGT has more shares outstanding

The number of shares outstanding for COGT has been increased compared to 5 years ago.

COGT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

COGT has an Altman-Z score of 1.40. This is a bad value and indicates that COGT is not financially healthy and even has some risk of bankruptcy.

COGT has a better Altman-Z score (1.40) than 64.87% of its industry peers.

A Debt/Equity ratio of 0.28 indicates that COGT is not too dependend on debt financing.

The Debt to Equity ratio of COGT (0.28) is worse than 70.26% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.28
Debt/FCF	N/A
Altman-Z	1.4

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 4.19 indicates that COGT has no problem at all paying its short term obligations.

COGT has a Current ratio (4.19) which is comparable to the rest of the industry.

A Quick Ratio of 4.19 indicates that COGT has no problem at all paying its short term obligations.

COGT has a Quick ratio (4.19) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	4.19
Quick Ratio	4.19

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.02% over the past year.

EPS 1Y (TTM)27.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%10.17%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, COGT will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.15% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-7.84%

EPS Next 2Y3.96%

EPS Next 3Y15.45%

EPS Next 5Y19.15%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

COGT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COGT. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as COGT's earnings are expected to grow with 15.45% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y3.96%

EPS Next 3Y15.45%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for COGT!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

COGENT BIOSCIENCES INC

NASDAQ:COGT (9/26/2025, 1:15:10 PM)

14.05

+0.76 (+5.72%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-05 2025-08-05/bmo

Earnings (Next)11-10 2025-11-10/bmo

Inst Owners103.04%

Inst Owner Change1.33%

Ins Owners0.04%

Ins Owner Change0%

Market Cap1.96B

Analysts82.22

Price Target20.6 (46.62%)

Short Float %9.47%

Short Ratio4.6

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)12.16%

Min EPS beat(2)11.44%

Max EPS beat(2)12.87%

EPS beat(4)3

Avg EPS beat(4)23.39%

Min EPS beat(4)-10.87%

Max EPS beat(4)80.14%

EPS beat(8)3

Avg EPS beat(8)4.79%

EPS beat(12)5

Avg EPS beat(12)3.15%

EPS beat(16)5

Avg EPS beat(16)-2.5%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)8.02%

PT rev (3m)25.54%

EPS NQ rev (1m)-0.8%

EPS NQ rev (3m)2.52%

EPS NY rev (1m)0%

EPS NY rev (3m)5.84%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	12.66
P/tB	12.66
EV/EBITDA	N/A

EPS(TTM)-1.81

EYN/A

EPS(NY)-1.81

Fwd EYN/A

FCF(TTM)-1.68

FCFYN/A

OCF(TTM)-1.67

OCFYN/A

SpS0

BVpS1.11

TBVpS1.11

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-74.4%
ROE	-131.89%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-52.46%

ROA(5y)-51.99%

ROE(3y)-64.47%

ROE(5y)-60.7%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.28
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	40.67%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.19
Quick Ratio	4.19
Altman-Z	1.4

F-Score2

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)321.08%

Cap/Depr(5y)421.98%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)27.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%10.17%

EPS Next Y-7.84%

EPS Next 2Y3.96%

EPS Next 3Y15.45%

EPS Next 5Y19.15%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-22.91%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-4%

EBIT Next 3Y7.82%

EBIT Next 5YN/A

FCF growth 1Y-64.18%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-72.67%

OCF growth 3YN/A

OCF growth 5YN/A

COGENT BIOSCIENCES INC (COGT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens